Abstract
Prostate cancer diagnosis and treatment is fast emerging as a major health care issue in the United States. However, there are great uncertainties about the value of specific tests and therapies. Imaging modalities play a major role in the current management of patients with prostate cancer and this role is likely to expand in the future. Transrectal ultrasound is used to identify non-palpable lesions, direct systematic biopsies, determine gland volume and stage prostate cancers. For staging skeletal metastases, the bone scan is acknowledged as the best method, however controversy surrounds its routine use in patients with low prostate specific antigen (PSA) values. Computed tomography (CT) and transrectal ultrasound have limited value in detecting extracapsular disease but CT can be used in conjunction with percutaneous biopsy to identify nodal metastases. The role of Endorectal coil MRI is currently evolving in the wake of a disappointing multiinstitutional trial but MRI still holds the most promise for accurately detecting local extent of prostate cancer. New radiolabeled techniques with monoclonal antibodies and peptide imaging are also having early but promising results. The role of imaging in prostate cancer is continuing to evolve as technology and knowledge about prostate cancer biology improves and health care economics force a more judicious use of imaging resources.
Similar content being viewed by others
References
Scardino PT. Early detection of prostate cancer.Urol Clin North Am 1989;16:635–655
Cupp MR, Oesterling J. Prostate specific antigen, digital rectal examination, and transrectal ultrasonography: their roles in diagnosing early prostate cancer.Mayo Clin Proc 1993;68:297–306
Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer. A decision analytic view [see comments].JAMA 1994;272:773–780
Lee F Jr, Torp-Pederson S, Littrup PJ, McCleary RD, McHugh TA, Smid AP, Stella PJ, Borlaza GS. Hypoechoic lesions of the prostate: clinical relevance of tumor size, digital rectal examination and prostate specific antigen.Radiology 1989;170:609–613
Olsson C. Prostatic cancer.Kidney Int 1993;43:955–965
Stamey T. Making the most out of six systematic sextant biopsies.Urology 1995;45:2–12
Hricak H, Jeffrey RB, Dooms GC, Tanagho EA. Evaluation of prostate size: a comparison of ultrasound and magnetic resonance imaging.Urol Radiol 1987;9:1–8
Schmidt JD. Clinical diagnosis of prostate cancer.Cancer 1992;70:221–224
Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer.New Eng J Med 1994;330:242–248
Schmidt JD. Localized prostate cancer: prostatectomy versus interstitial implantation [editorial].J Surg Oncol 1992;49:1–2
Robinson RG. Strontium-89-precursor targeted therapy for pain relief of blastic metastatic disease.Cancer 1993;72:3433–3435
Robinson RG, Preston DF, Baxter KG, Dusing RW, Spicer JA. Clinical experience with strontium-89 in prostatic and breast cancer patients.Semin Oncol 1993;20:44–48
Robinson RG, Preston DF, Spicer JA, Baxter KG. Radionuclide therapy of intractable bone pain: emphasis on strontium-89.Semin Nucl Med 1992;22:28–32
Schmitz-Drager BJ, Ebert T, Ackermann R. Clinical staging in carcinoma of the prostate: current aspects.Recent Results Cancer Res 1993;126:31–42
Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer [see comments].JAMA 1993;269:57–60
Chybowski FM, Keller J, Bergstralh EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.J Urol 1991;145:313–318
Engeler CE, Wasserman NF, Zhang G. Preoperative assessment of prostatic carcinoma by computerized tomography.Urology 1992;40:346–350
Ebert T, Scmitz-Drager BJ, Burrig KF, Miller S, Pauli N, Kahn T, Ackermann R. Accuracy of imaging modalities in staging the local extent of prostate cancer.Urol Clin North Am 1991;18:453–456
Friedland GW, Chang P. The role of imaging in prostate cancer.Radiol Clin North Am 1991;29:581–589
Oyen RH, Van Poppel H, Ameye FE, Van de Voorde WA, Baert AL, Baert LV. Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine needle aspiration biopsy: prospective study of 285 patients.Radiology 1994;190:315–322
Amis ES Jr. Role of CT and CT-guided nodal biopsy in staging of prostatic cancer.Radiology 1994;190:309–310
Rifkin MD, Zerhouni EA, Gatsonis CA, et al. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer.N Engl J Med 1990;323:622–626
Clements R, Griffith G, Peeling WB. Staging prostatic cancer [review].Clin Radiol 1992;46:225–231
Pontes JE, Eisenkraft S, Watanabe H, et al. Preoperative evaluation of localized prostatic carcinoma by transrectal sonography.J Urol 1985;134:289–291
Hernandez AD, Smith JA. Transrectal ultrasonography for the early detection and staging of prostate cancer.Urol Clin North Am 1990;17:745–753
Terris MK, McNeal JE, Stamey TA. Invasion of the seminal vesicles by prostatic cancer: detection with transrectal US with pathologic correlation.Radiology 1990;155:811–815
Schiebler ML, Schnall MD, Pollack HM, Lenkinski RE, Tomaszewski JE, Wein AJ, Whittington R, Rasuschning W, Kressel HY. Current role of MR imaging in the staging of adenocarcinoma of the prostate.Radiology 1993;189:339–352
Tempany CM, Zhou Z, Zerhouni EA, et al. Staging of prostate cancer: results of radiology diagnostic oncology group project comparison of three MR imaging techniques.Radiology 1994;192:47–54
Schnall MD, Itai Y, Tomaszewski J, Pollack HM, Lenkinski RE, Kressel HY. Prostate cancer: local staging with endorectal surface coil MR imaging.Radiology 1991;178:797–802
Chelsky MJ, Schnall MD, Seidmon EJ, Pollack HM. Use of endorectal surface coil magnetic resonance imaging for local staging of prostate cancer.J Urol 1993;150:391–395
Rosen MA, Goldstone L, Lapin S, Wheeler T, Scardino PT. Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens.J Urol 1992;148:331–337
Kier R, Wain S, Troiano R. Fast spin echo MR images of the pelvis obtained with a phased array coil. Value in localizing and staging prostatic carcinoma.Am J Roent 1993;161:601–606
Neal CE, Swenson LE, Fanning J, Texter JH. Monoclonal anti-bodies in ovarian and prostate cancer.Semin Nucl Med 1993;23:114–126
Maguire RT, Pascucci VL, Maroli AN, Gulfo JV. Immunoscin-tigraphy in patients with colorectal, ovarian, and prostate cancer. Results with site-specific immunoconjugates.Cancer 1993;72: 3453–3462
Babaian RJ, Sayer J, Podoloff DA, Steelhammer LC, Bhadkamkar VA, Gulfo JV. Radioimmunoscintigraphy of pelvic lymph nodes with 111indium-labeled monoclonal antibody CYT-356.J Urol 1994;152:1952–1955
Podoloff DA, Bhadkamar V, Haynie TP, et al. Imaging consideration of I-131 labelled CC49 monoclonal antibody.J Nucl Med 1992;33:1001–1002
Onik GM, Cohen JK, Reyes GD, Rubinsky B, Chang Z, Baust J. Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate.Cancer 1993;72:1291–1299
Wallner K, Roy J, Zelefsky M, Fuks Z, Harrison L. Short-term freedom from disease progression after 1–125 prostate implantation.Int J Radiat Oncol Biol Phys 1994;30:405–409
van't Riet A, te Loo HJ, Ypma AF, et al. Ultrasonically guided transperineal seed implantation of the prostate: modification of the technique and qualitative assessment of implants.Int J Radiat Oncol Biol Phys 1992;24:555–558
Weissleder R, Heautot JF, Schaffer BK, Nossiff N, Papisov MI, Bogdanov A Jr, Brady TJ. MR lymphography: study of a high-efficiency lymphotrophic agent.Radiology 1994;191:225–230
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Choyke, P.L. Imaging of prostate cancer. Abdom Imaging 20, 505–515 (1995). https://doi.org/10.1007/BF01256700
Issue Date:
DOI: https://doi.org/10.1007/BF01256700